---
title: "Boundless Bio CEO to Join Guggenheim Emerging Outlook Biotech Summit Fireside Chat"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274967305.md"
datetime: "2026-02-05T12:00:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274967305.md)
  - [en](https://longbridge.com/en/news/274967305.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274967305.md)
---

# Boundless Bio CEO to Join Guggenheim Emerging Outlook Biotech Summit Fireside Chat

Boundless Bio Inc. will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, in New York, NY. The session will feature President and CEO Zachary Hornby and will be available via live and archived webcast on the company’s website. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boundless Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9649057-en) on February 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [BOLD.US](https://longbridge.com/en/quote/BOLD.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [Boundless Bio Terminates Major Long-Term San Diego Lease](https://longbridge.com/en/news/282594597.md)
- [BUZZ-BioXcel rises as trial starts for its stress disorder drug in trauma victims](https://longbridge.com/en/news/282027350.md)
- [Should Positive Elsunersen Data And Relutrigine Priority Review Shift the Narrative for Praxis (PRAX) Investors?](https://longbridge.com/en/news/282419526.md)
- [FDA issues complete response letter to Replimune’s RP1 for melanoma](https://longbridge.com/en/news/282511585.md)
- [PolyPid To Present New Phase 3 SHIELD II Data On D-PLEX100 At ESCMID 2026](https://longbridge.com/en/news/282665678.md)